Therefore, the combination of conventional anticancer therapies with molecularly targeted therapies, such as MEK1 and PI3K inhibitors might result in side effects, i.e., ErbB2 induction, that require further studies to develop new strategies that selectively kill cancer cells and overcome drug resistance. This evidence concerns the gene MAP2K1 and cancer.